The pharmagenic enrichment score approach has been demonstrated to identify individuals with elevated genetic risk within biological systems that can be targeted by drugs. Importantly, this includes patients who otherwise have low overall genetic risk for a disorder when assessed using the traditional approach taking the entire DNA sequence (genome) into account. In other words, genetic risk identified by our platform related to the mode of action of drugs is more sensitive for treatment formulation than risk information from throughout the genome. For example, in schizophrenia we have shown that patients with low genome-wide genetic risk are more likely to have high risk in clinically-actionable pathways, revealed by our platform, which can be targeted by candidate drugs. Our extensive preclinical data supports that our platform provides insights that are unique and informative for treatment.